Am J Transplant, Volume 18, Suppl 3 Archives - Page 50 of 211 - ATC Abstracts

2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
P. Malvezzi,¹ C. Fischman,² T. Jouve,¹ B. Janbon,¹ P. Heeger,² L. Rostaing,¹ P. Cravedi.²
¹Service de Néphrologie, Dialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France; ²Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…
2018 American Transplant Congress
Living Donor Nephrectomy: Is It as Safe as It Can Be? Analysis of Living Donor Deaths in the United States
D. Keith,¹ J. Brown,² K. Andreoni.³
¹Medicine, Sacred Heart Hospital, Pensacola, FL; ²President, Clinical Integration Solutions, LLC, Health Safety Consultancy Company, New York, NY; ³Surgery, University of Florida, Gainesville, FL.
The reported rate of death from living donor nephrectomy is 3 in 10,000 donations. Although this risk is low, the important question is how many…
2018 American Transplant Congress
Self-Reported Post-Surgical Pain Following Living Kidney Donation
A. Fleishman,¹ J. Schold,² P. Morrissey,³ J. Whiting,⁴ J. Vella,⁴ L. Kayler,⁵ D. Katz,⁶ J. Jones,⁶ B. Kaplan,⁷ M. Pavlakis,¹ D. Mandelbrot,⁸ J. Rodrigue.¹
¹Beth Israel Deaconess Medical Center, Boston; ²Cleveland Clinic, Boston; ³Rhode Island Hospital, Providence; ⁴Maine Medical Center, Portland; ⁵University of Buffalo, Buffalo; ⁶University of Iowa, Iowa City; ⁷May Clinic, Scottsdale; ⁸University of Wisconsin, Madison.
The Kidney Donor Outcomes Cohort (KDOC) is an NIH-funded observational cohort study evaluating outcomes in living kidney donors (LKDs) at 6 US centers. LKDs completed…
2018 American Transplant Congress
Further In Vivo and In Vitro Evidence That Anti-CD40 MABS Do Not Induce Thromboembolism
T. Rubic-Schneider, B. Christen, N. Runser Loll, D. Garcia, E. Erard, T. Flandre, B. Cochin de Billy, S. Nock, S. Côté, J. Rush, P. Ulrich.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Clinical trials with non-silenced anti-CD40L (anti-CD154) monoclonal antibodies (mAb) in patients with systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP) were halted after unexpected…
2018 American Transplant Congress
Urological Complications of Prophylactic Ureteral Stent vs. No Stent in Kidney Transplant Recipients at Erie County Medical Center (ECMC)
M. Hamid,¹ J. Kumar,¹ S. Anjum,¹ S. Patel,² G. Gudleski,⁴ S. Mietz,³ M. Ott,³ S. Chang.¹
¹Nephrology, SUNY Buffalo, Buffalo, NY; ²Surgery, SUNY Buffalo, Buffalo, NY; ³Pharmacy, Erie County Medical Center, Buffalo, NY; ⁴Medicine, SUNY Buffalo, Buffalo, NY.
Introduction:Complications after kidney transplant (tx) commonly originate from ureterovesical anastomosis, it accounts for 3-9% of urinary complications. Due to the difference in the surgical preference,…
2018 American Transplant Congress
A “Multi-Omic” Analysis of Proteome and Metabolome for Acute Rejection and PVAN in Kidney Transplantation
T. Sigdel, J. Yang, M. Sarwal.
Surgery, UCSF, San Francisco.
Background: Most effort in identifying biomarkers have used gene expression analyses. Proteomics and metabolomics are useful to identify surrogate biomarkers in monitoring transplanted kidney and…
2018 American Transplant Congress
Incidence of Rejection and Antibody Formation after Immunosuppression Reduction in Patients with Biopsy Proven Polyomavirus Nephropathy
M. Kleman, R. Detwiler, H. Singh, V. Nickeleit.
University of North Carolina, Chapel Hill, NC.
The purpose of this study is to determine the incidence of rejection and donor specific antibody (DSA) formation after immunosuppression reduction in patients with biopsy…
2018 American Transplant Congress
Clinical Outcomes of Late Conversion to Once-Daily Tacrolimus after Liver Transplant
D. Kim,¹ Y. Jung,¹ J. Lee,¹ J. Lee,¹ S. Kim,² M. Ju,¹ M. Kim,¹ S. Kim,¹ D. Joo.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Surgery, Yonsei University Wonju Hospital, Wonju, Korea.
BackgroundSince a once-daily tacrolimus (TAC-OD) has been introduced in the field of transplantation, many studies reported advantages of the new drug, such as the better…
2018 American Transplant Congress
Pre Liver Transplant (LT) Prediction of Surgical Complexity by Recipient Risk Grading and Optimizing Outcomes: The Ochsner Experience
H. Sharma,¹ H. Bohorquez,^1,2 D. Bruce,¹ J. Seal,¹ A. Cohen,^1,2 E. Bugeaud,¹ I. Carmody,^1,2 D. Sonnier,¹ A. Mathur,¹ D. Marroquin,¹ M. Voltz,¹ L. DeGregorio,¹ G. Loss.^1,2
¹Multi-Organ Transplant Institute, Ochsner Health System, New Orleans, LA; ²School of Medicine, University of Queensland, New Orleans, LA.
Background: Ochsner Unit has been assigning the potential recipient with surgical complexity category since 2015 to preempt surgical risk .Aim: To review outcomes after the…
2018 American Transplant Congress
Impact of Providing Care Locally Compared to at a Transplant Center for Pre-And Posttransplant Liver Patients
R. Shahbazov,¹ K. Knapp,² S. Tsutsui,² A. Nickkholgh,¹ P. Northup,³ J. Oberholzer,¹ D. Maluf,¹ M. Shiffman,⁴ S. Pelletier.¹
¹Surgery, University of Virginia Healthsystem, Charlottesville, VA; ²University of Virginia School of Medicine, University of Virginia Healthsystem, Charlottesville, VA; ³Gastroenterology, University of Virginia Healthsystem, Charlottesville, VA; ⁴Secours Liver Institute of Richmond, Secours Liver Institute of Richmond, Richmond, VA.
There is a potential to improve patient satisfaction as well as access to liver transplantation (LT). AIM: This study evaluated outcomes of LT recipients whose…